Patents by Inventor Radmila Micanovic
Radmila Micanovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11053290Abstract: Embodiments of the present disclosure provide polypeptides, related materials and compositions, and methods for their use. In certain embodiments, the present disclosure provides a monomeric Tamm-Horsfall Protein polypeptide, or a biologically active truncation thereof. Other embodiments provide polynucleotides encoding a polypeptide described herein, nucleic acid expression vectors including the polynucleotides, and recombinant host cells including the expression vector. Yet other embodiments provide pharmaceutical compositions including a polypeptide described herein. Also provided are methods for treating a renal disease, disorder, or condition in a subject and/or modulating an immune response in a subject.Type: GrantFiled: October 28, 2016Date of Patent: July 6, 2021Assignees: Indiana University Research and Technology Corporation, The United States Government as Represented by the Department of Veterans AffairInventors: Tarek Maurice Ashkar, Radmila Micanovic
-
Publication number: 20180305420Abstract: Embodiments of the present disclosure provide polypeptides, related materials and compositions, and methods for their use. In certain embodiments, the present disclosure provides a monomeric Tamm-Horsfall Protein polypeptide, or a biologically active truncation thereof. Other embodiments provide polynucleotides encoding a polypeptide described herein, nucleic acid expression vectors including the polynucleotides, and recombinant host cells including the expression vector. Yet other embodiments provide pharmaceutical compositions including a polypeptide described herein. Also provided are methods for treating a renal disease, disorder, or condition in a subject and/or modulating an immune response in a subject.Type: ApplicationFiled: October 28, 2016Publication date: October 25, 2018Applicant: Indiana University Research and Technology CorporationInventors: Tarek Maurice Ashkar, Radmila Micanovic
-
Patent number: 8883726Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.Type: GrantFiled: August 13, 2013Date of Patent: November 11, 2014Assignee: Eli Lilly and CompanyInventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Malgorzata Donata Gonciarz, Radmila Micanovic
-
Publication number: 20130324460Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.Type: ApplicationFiled: August 13, 2013Publication date: December 5, 2013Applicant: Eli Lilly and CompanyInventors: Craig Duane DICKINSON, David Albert DRIVER, Ryan James DARLING, Malgorzata Donata GONCIARZ, Radmila MICANOVIC
-
Patent number: 8541369Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.Type: GrantFiled: September 25, 2012Date of Patent: September 24, 2013Assignee: Eli Lilly and CompanyInventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Maigorzata Donata Gonciarz, Radmila Micanovic
-
Patent number: 7655627Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: GrantFiled: December 7, 2005Date of Patent: February 2, 2010Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Patent number: 7622445Abstract: The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: GrantFiled: August 25, 2005Date of Patent: November 24, 2009Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Patent number: 7582607Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: GrantFiled: July 26, 2005Date of Patent: September 1, 2009Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Publication number: 20090118190Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: ApplicationFiled: January 6, 2009Publication date: May 7, 2009Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
-
Patent number: 7491697Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: GrantFiled: December 1, 2004Date of Patent: February 17, 2009Assignee: Eli Lilly and CompanyInventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
-
Publication number: 20080103096Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: ApplicationFiled: July 26, 2005Publication date: May 1, 2008Applicant: ELI LILLY AND COMPANYInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Publication number: 20070299007Abstract: The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: ApplicationFiled: August 25, 2005Publication date: December 27, 2007Inventors: Christopher Frye, Lihua Huang, Radmila Micanovic
-
Publication number: 20070293430Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: ApplicationFiled: December 7, 2005Publication date: December 20, 2007Inventors: Christopher Frye, Lihua Huang, Radmila Micanovic
-
Patent number: 7271149Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.Type: GrantFiled: November 29, 2001Date of Patent: September 18, 2007Assignee: Eli Lilly and CompanyInventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Rainbow Tschang
-
Publication number: 20070161087Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.Type: ApplicationFiled: January 11, 2007Publication date: July 12, 2007Inventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Tschang
-
Publication number: 20070142278Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: ApplicationFiled: December 1, 2004Publication date: June 21, 2007Inventors: John Beals, Christopher Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Strifler, Radmila Micanovic
-
Publication number: 20070100133Abstract: The present invention addresses the need for better pharmaceutical agents for teating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity in vivo. The invention further provides methods for preparing these derivatived proteins which involves the use of a linkerless aldehyde modification process.Type: ApplicationFiled: September 14, 2006Publication date: May 3, 2007Inventors: John Beals, Wolfgang Glaesner, Radmila Micanovic, Rohn Millican, Derrick Witcher
-
Publication number: 20060147945Abstract: The present invention provides nucleic acid sequences encoding novel human proteins. These novel nucleic acids are useful for constructing the claimed DNA vectors and host cells of the invention and for preparing the claimed nucleic acids, recombinant proteins and antibodies that are useful in the claimed methods and medical uses.Type: ApplicationFiled: January 6, 2005Publication date: July 6, 2006Inventors: Brian Edmonds, Radmila Micanovic, Weijia Ou, Eric Su, Sheng-Hung Tschang, He Wang
-
Patent number: 6965012Abstract: Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.Type: GrantFiled: March 20, 2000Date of Patent: November 15, 2005Assignee: Eli Lilly and CompanyInventors: Gerald Wayne Becker, Fredric Jay Cohen, Patricia Ann Gonzalez-DeWhitt, John Edward Hale, Radmila Micanovic, Christy Michelle Newton, Timothy Wayne Noblitt, Radhakrishnan Rathnachalam, Sheng-Hung Rainbow Tschang, Derrick Ryan Witcher, Victor John Wroblewski
-
Publication number: 20050014679Abstract: The present invention provides an insulin molecule that provides a protracted, even basal duration of action. The insulin molecule comprises a modification at the N-terminus of the A-chain, optionally a modification at the N-terminus of the B-chain, a modification at a B-chain lysine, and optionally a modification at the C-terminus of the A-chain. The present invention also provides a method of treating diabetes mellitus comprising administering the insulin molecule.Type: ApplicationFiled: December 12, 2002Publication date: January 20, 2005Inventors: John Beals, Michael DeFelippis, Richard DiMarchi, Wayne Kohn, Radmila Micanovic, Sharon Myers, Kingman Ng, Lianshan Zhang